{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:02:59Z","timestamp":1783569779742,"version":"3.55.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Belantamab mafodotin (belamaf), an antibody-drug conjugate targeting B-cell maturation antigen, has demonstrated single-agent activity in relapsed\/refractory multiple myeloma (RRMM) but is associated with ocular toxicity. This phase 1\/2 study evaluated the safety and preliminary efficacy of belamaf administered every 8 weeks in combination with carfilzomib, lenalidomide, and dexamethasone (KRd-b) in patients with RRMM. Eligible patients had received at least 1 previous line of therapy and had not progressed on full-dose lenalidomide. In the dose-escalation phase (3+3 design), belamaf was administered at 1.4 or 1.9 mg\/kg every 8 weeks. The recommended phase 2 dose was 1.9 mg\/kg, with no dose-limiting toxicities at this level. Among 19 patients treated, the overall response rate was 89.5%, and 78.9% achieved very good partial response or better, with minimal residual disease negativity in all complete responders. At a median follow-up of 19.3 months, 24-month progression-free survival and overall survival rates were 74.3% and 85.1%, respectively. Keratopathy occurred in 94.7% of patients but was mostly grade 1 to 2, reversible, and manageable without permanent discontinuation. Grade \u22653 keratopathy (31.6%) was comparable with historical rates despite the less frequent dosing. Other adverse events, including hematologic and gastrointestinal toxicities, were manageable and consistent with known profiles of KRd or belamaf. The combination demonstrated deep and durable responses, including in patients at high-risk and with lenalidomide maintenance dose-refractory disease. These results support the feasibility of KRd-b with extended-interval belamaf and warrant further evaluation in phase 2 trials to confirm its clinical benefit in RRMM. This trial is registered at www.clinicaltrials.gov as NCT04822337.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019050","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T20:52:27Z","timestamp":1771620747000},"page":"2925-2936","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"first","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"},{"name":"2Department of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Symanowski","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra","family":"Robinson","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Flynn","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Norek","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Cox","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Plott","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Bumgarner","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darynne","family":"Rhinehardt","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xhevahire","family":"Begic","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Ndiaye","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Robinson","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0982-2345","authenticated-orcid":false,"given":"Reed","family":"Friend","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"},{"name":"2Department of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Paul","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"},{"name":"2Department of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Varga","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"},{"name":"2Department of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ferreri","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"},{"name":"2Department of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0028-3720","authenticated-orcid":false,"given":"Mauricio","family":"Pineda-Roman","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"},{"name":"2Department of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-8356","authenticated-orcid":false,"given":"David","family":"Foureau","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"},{"name":"2Department of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9019-7438","authenticated-orcid":false,"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"},{"name":"2Department of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter","family":"Voorhees","sequence":"additional","affiliation":[{"name":"1Atrium Health Levine Cancer, Atrium Health Wake Forest Comprehensive Cancer Center, Charlotte, NC"},{"name":"2Department of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"9","key":"2026050815182022500_bib1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"2026050815182022500_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026050815182022500_bib3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"14","key":"2026050815182022500_bib4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2026050815182022500_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"2026050815182022500_bib6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJMc2410841","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2026050815182022500_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"2026050815182022500_bib8","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026050815182022500_bib9","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2022.10.008","article-title":"Standardizing clinical workflow for assessing minimal residual disease by flow cytometry in multiple myeloma","volume":"23","author":"Foureau","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2026050815182022500_bib10","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"10297","key":"2026050815182022500_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"issue":"4","key":"2026050815182022500_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"2026050815182022500_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026050815182022500_bib14","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"16 suppl","key":"2026050815182022500_bib15","first-page":"7540-7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026050815182022500_bib16","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"Hemasphere"},{"issue":"4","key":"2026050815182022500_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026050815182022500_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"2026050815182022500_bib19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2925\/2515756\/blooda_adv-2025-019050-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2925\/2515756\/blooda_adv-2025-019050-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:18:28Z","timestamp":1778267908000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/2925\/566678\/Belantamab-mafodotin-carfilzomib-lenalidomide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019050","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,4,29]]}}}